União Europeia - maltês - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatonin - sleep inizjattiva u maintenance disorders - psikolettiċi - circadin huwa indikat bħala monoterapija għat-trattament għal żmien qasir ta 'nuqqas ta' rqad primarju kkaratterizzat minn kwalità fqira ta 'rqad f'pazjenti li għandhom 55 sena jew aktar.

União Europeia - maltês - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - daliresp huwa indikat għall-manutenzjoni trattament severi kronika eliminat pulmonari marda (copd) (fev1 bronchodilator wara inqas minn 50% mbassra) assoċjati ma ' bronchitis kroniċi fil-pazjenti adulti bi storja ta ' spiss exacerbations bħala żieda trattament bronchodilator.

União Europeia - maltês - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - duloxetine - neuropatiji dijabetiċi - psychoanaleptics, - trattament ta 'uġigħ newropatiku periferali dijabetiku fl-adulti.

União Europeia - maltês - EMA (European Medicines Agency)

krka, d.d., novo mesto - repaglinide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - repaglinide huwa indikat fil-pazjenti bl-dijabete tat-tip-2 (mhux-insulina - dipendenti diabetes mellitus (niddm)) tagħhom hyperglycaemia jistgħu aktar jiġu kkontrollati b'mod sodisfaċenti minn dieta, piż tnaqqis u l-eżerċizzju. repaglinide huwa indikat ukoll flimkien ma 'metformin f'pazjenti bid-dijabete tat-tip-2 li mhumiex ikkontrollati b'mod sodisfaċenti fuq metformin waħdu. il-kura għandha tinbeda bħala żieda mad-dieta u l-eżerċizzju biex ibaxxi l-glucose fid-demm fir-rigward ta'l-ikel.

União Europeia - maltês - EMA (European Medicines Agency)

roche registration gmbh - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunosoppressanti - esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.

União Europeia - maltês - EMA (European Medicines Agency)

gedeon richter ltd  - ulipristal acetate - leiomyoma - - ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema, - ulipristal aċetat huwa indikat għal trattament pre-operative ta moderat għal sintomi severi ta fibroids uterini fin-nisa adulti ta ' l-età riproduttivi. ulipristal acetate huwa indikat għat-trattament intermittenti moderat għal sever is-sintomi tal-fibrojdi fl-utru f'nisa adulti ta ' età riproduttiva.

União Europeia - maltês - EMA (European Medicines Agency)

bial - portela ca, s.a. - eslicarbazepine acetate - epilessija - anti-epilettiċi, - exalief huwa indikat bħala terapija aġġuntiva f'adulti b'aċċessjonijiet ta 'bidu parzjali b'ġeneralizzazzjoni sekondarja jew mingħajrha.

União Europeia - maltês - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - neoplasmi prostatiċi - terapija endokrinali - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

União Europeia - maltês - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - afatinib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - giotrif bħala monoterapija hija indikata għat-trattament ofepidermal growth factor receptor (egfr) tki pazjenti adulti naΐve għal kura bil-lokalment avvanzat jew dak metastatiku li mhux ta 'ċelluli żgħar kanċer tal-pulmun (nsclc) ma' l-attivazzjoni tal-egfr-mutazzjoni tal - (s);lokalment avvanzat jew metastatiku nsclc tal-kanser skwamuż tar-istoloġija tal-progress fuq jew wara ibbażat fuq il-platinu ' kimoterapija.

União Europeia - maltês - EMA (European Medicines Agency)

novartis europharm limited - imatinib - precursor cell lymphoblastic leukemia-lymphoma; gastrointestinal stromal tumors; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - aġenti antineoplastiċi - glivec is indicated for the treatment of , adult and paediatric patients with newly diagnosed philadelphia-chromosome (bcr-abl)-positive (ph+) chronic myeloid leukaemia (cml) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed philadelphia-chromosome-positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (mds / mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and / or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfra rearrangement. , l-effett ta 'glivec fuq l-eżitu ta' l-għadam-trapjant tal-mudullun għadu ma ġiex determinat. glivec is indicated for: , the treatment of adult patients with kit (cd 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (gist);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pazjenti li għandhom livell baxx jew l-riskju baxx ħafna ta ' rikorrenza m'għandhomx jirċievu kura awżiljarja;, il-kura ta'pazjenti adulti li ma jistax jitneħħa dermatofibrosarcoma protuberans (dfsp) u pazjenti adulti bil-rikorrenti u / jew metastatiku dfsp li mhumiex eliġibbli għall-kirurġija. , f'pazjenti adulti u pedjatriċi, l-effikaċja ta 'glivec hija bbażata fuq globali ematoloġiċi u ċitoġenetiċi-rati ta' rispons u sopravivenza mingħajr progressjoni f'cml, fuq ematoloġiċi u ċitoġenetiċi-rati ta 'rispons f'ph+ all, mds / mpd, fuq il-rati ta' rispons ematoloġiku f'hes / cel u dwar l-objettiv tal-rati ta ' rispons fil-pazjenti adulti li ma jistax jitneħħa u / jew metastiku-gist u dfsp u dwar ir-rikorrenza-sopravivenza mingħajr progressjoni fl-adjuvant gist. l-esperjenza bi glivec f'pazjenti b'mds / mpd assoċjati ma ' tibdil fil-ġene pdgfr hija limitata ħafna (ara taqsima 5. Ħlief fil għadhom kif ġew dijanjostikati cml ta ' fażi kronika, m'hemmx provi kliniċi li juru benefiċċju kliniku jew żieda fis-sopravivenza għal dawn il-mard.